BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug ...

Background: PV is characterized by red blood cell overproduction. Rusfertide is a subcutaneous (SC), self-injected, first-in-class peptide hepcidin mimetic that decreases erythrocytosis. VERIFY ...

The E2810 double-blind, placebo-randomized phase III trial was conducted through the National Clinical Trials Network and was led by Eastern Cooperative Oncology Group (ECOG)-ACRIN with participation ...